Dr. SvenRihm

Counsel

Múnich + 49.89.20.60.42.200

Contacto:

Compartir

Dr. Sven Rihm is a German and European patent lawyer with more than 15 years experience in the field of intellectual property. Sven advises clients in all aspects of patent prosecution as well as invalidation and litigation of intellectual property matters. He represents clients in all technical aspects of organic, inorganic, and polymer chemistry as well as in technologies related to life science, biotechnology, and pharmaceuticals.

Sven represents clients such as BioMarin Pharmaceuticals, Celgene Corporation, Idenix Pharmaceuticals, PTC Therapeutics, and Signal Pharmaceuticals. Among other matters, he was involved in defending European patents of Idenix Pharmaceuticals covering nucleoside analogues for treating HCV infections in opposition proceedings.

Prior to joining Jones Day, Sven practiced at one of Germany's largest law firms and at a small German IP boutique. He has handled numerous oppositions, freedom-to-operate and due diligence analyses, and infringement actions. He has represented clients in oral proceedings before the Opposition Division and the Boards of Appeal at the European Patent Office.

Sven is a member of the German Patent Lawyer's Association (PAK), the Institute of Professional Representatives before the European Patent Office (epi), the International Federation of Industrial Property Attorneys (FICPI), and the Association of Intellectual Property Experts (VPP).

Experiencia

  • LyondellBasell acquires APKJones Day advised LyondellBasell in the acquisition of APK AG in Merseburg, Germany.
  • Idenix enforces patent against Gilead in Germany over sofosbuvirJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in Landgericht Düsseldorf in Germany over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • Idenix defends nucleoside analogue patent in EPO opposition against five opponentsJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs.
  • Milliken & Company acquires Zebra-chemJones Day advised Milliken & Company in its acquisition of Zebra-chem GmbH, a global chemicals company known for its peroxide and blowing agent masterbatches.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Global manufacturer of specialty adhesives enforces hotmelt adhesive patent against major German competitorJones Day represents a manufacturer of specialty adhesives in patent litigation against a major German competitor before the courts in Düsseldorf and the German Federal Patent Court.
    •

    October 2022 Alert

    The Days are Numbered for the EPO's 10-Day Rule

    April 2020 Alert

    COVID-19 Accelerates Digital Transformation at the European Patent Office

    March 2017 Commentary

    Antidote to Toxic Divisionals—European Patent Office Rules on Partial Priorities

    June 2015 Alert

    The EPO's Undisclosed Disclaimers Trap—A Possible Way Out

    Antes del envío, por favor tenga en cuenta:

    la información contenida en www.jonesday.com es para uso general y no constituye asesoramiento legal. El envío y recepción de este correo electrónico no pretenden crear una relación abogado-cliente. La información que envíe a cualquier persona de nuestra Firma no tendrá carácter confidencial o privilegiado excepto en el caso de que estemos actúando en su representación. Si envía este correo electrónico, confirma que ha leído y comprendido este aviso.